

# William B. Trattler, MD

[The Center for Excellence in Eye Care](#)

8940 North Kendall Drive, Suite 400E

Miami, Florida 33176

(305) 598-2020

[wtrattler@gmail.com](mailto:wtrattler@gmail.com)

NPI # 1093730996

## **CERTIFICATION**

10/98 BOARD CERTIFIED IN OPHTHALMOLOGY  
1/1/2009: Recertified (expires 12/31/2018)

## **EDUCATION**

7/96-7/97 UNIVERSITY OF TEXAS- SOUTHWESTERN MEDICAL SCHOOL, Dallas, Texas  
Cornea and External Disease Fellowship

7/93- 7/96 UNIVERSITY OF PENNSYLVANIA/ SCHEIE EYE INSTITUTE  
Ophthalmology Residency

7/92-6/93 MOUNT SINAI MEDICAL CENTER, Miami Beach, Florida  
Internal Medicine Internship

9/88-5/92 UNIVERSITY OF MIAMI SCHOOL OF MEDICINE, Miami, Florida  
M.D. Degree with Research Distinction

9/84-6/88 DARTMOUTH COLLEGE, Hanover, New Hampshire  
Bachelor of Arts in Biology, *cum laude*

## **EMPLOYMENT**

7/97-Present THE CENTER FOR EXCELLENCE IN EYE CARE, Miami, Florida  
Private Practice; Subspecialty: Cornea, External Disease, & Refractive Surgery

7/02-7/06 BASCOM PALMER EYE INSTITUTE; Miami, FL (3 half days per month)  
Supervised Residents in the Bascom Palmer Eye Emergency Department  
Instructed residents in anterior segment surgery (cataract and corneal surgery)

7/97-7/01 V.A. HOSPITAL, Miami, Florida  
Surgical Staff: Supervising University of Miami ophthalmology residents in surgery & clinic

## **ACADEMIC APPOINTMENTS**

1/2012-Present Volunteer in the Department of Ophthalmology, Herbert Wertheim College of Medicine,  
Florida International University

7/2000-Present Volunteer Assistant Professor of Ophthalmology, Bascom Palmer Eye Institute

## **AWARDS AND HONORS**

November 2013 Senior Achievement Award, American Academy of Ophthalmology

Jan 9, 2012 Best Paper of Session, 6th Annual International Military Refractive Surgery Symposium; Jan 2012

# William B. Trattler, MD

- Jan 2012 Best Paper of the Day, Hawaiian Eye 2012 Meeting; Maui, Hawaii; Jan 2012
- 4/10 **PS250:** Identified by the publishers and editors of *Premier Surgeon* as one of the 250 top innovators in premium IOL implant surgery.
- 1/10 to present: Chief Medical Editor, Advanced Ocular Care  
website: <http://bmctoday.net/advancedocularcare/>
- 4/09 to present: Medical Editor: Eyetube.net.
- 4/09 Best Paper of Session; Quantitative Measurement of Accommodation in Phakic Eyes with a Wavefront Aberrometer; ASCRS 2009
- 12/07 to 7/2013 [Trusted LASIK Surgeons](#): Qualified and Listed at Trusted LASIK Surgeons, a LASIK directory service that screens surgeons based on experience, premier patient care, and professional credentials
- 11/06 Poster 664: *Delayed Epithelial Healing With Nepafenac Ophthalmic Solution* was "selected as one of the best posters at the 2006 Meeting of the American Academy of Ophthalmology", Las Vegas, NV; Nov 13 2006
- 05/06 Achievement Award; American Academy of Ophthalmology
- 04/06 Top 50 Cataract & Refractive Surgery Opinion Leaders, as voted on by readers of Cataract & Refractive Surgery Today.
- 2006, '08-11, '13-14 Aspen Invitational Refractive Symposium: Ski Race Champion
- 2002 Curtis D. Benton, Jr., MD Outstanding Young Ophthalmologist Leadership Award; This award is presented by the Florida Society of Ophthalmology (FSO) to a Florida ophthalmologist who has demonstrated leadership, service, competence and devotion to the high ethical and professional standards of the FSO.
- 1993-94 & 1995-96 Scheie Eye Institute Teaching Award
- 1994 Walter Stark, MD Award: "First Place Downhill Racer", Current Concepts in Ophthalmology meeting, Vail, Colorado
- 1991 Alpha Omega Alpha, Medical Honor Society
- 1989 John H. Fomon Memorial Research Fellowship, American Cancer Society: Support for ocular immunology research
- 1987 Reynolds Expedition Fund Grant: Supported shark research in Bimini, Bahamas

## RESEARCH POSITIONS/CLINICAL TRIALS

- 01/11 to 04/11 Insite Vision protocol C-10-303-001: Randomized Double Masked 14 day Study to Compare ISV-303 (0.075% Bromfenac in Durasite) to Vehicle and Xibrom in Post Cataract Surgery Volunteers.
- 07/10 to present Corneal Collagen crosslinking with riboflavin for Keratoconus, Pellucid, RK, and Post-LASIK ectasia in patients as young as 12 years old; Sponsored by CXLUSA
- 07/10 to present Multicenter Comparison of Tecnis Multifocal One Piece IOL to Restor D1 Multifocal Intraocular Lens; Sponsored by Abbott Medical Optics
- 07/10 to present Multicenter, Randomized, Masked Comparison of Bromfenac and Besifloxacin BID with Either Prednisolone BID or Loteprednol 0.5% BID for Prevention of Retinal Thickening and CME Following

# William B. Trattler, MD

Phacoemulsification; Unrestricted Grant provided by Bausch and Lomb; Clinicaltrials.gov identifier: NCT01193504

- 11/09 to 02/10: Vistakon CR1649: A Randomized, Double-Masked, Placebo-Controlled Dose-Response Study of the Safety and Efficacy of Two Dosage Strengths of the Bimatoprost Punctal Plug Delivery System (BPPDS) Compared to Placebo, Followed by an Open-Label, Single-Dose Bimatoprost 0.03% Ophthalmic Solution (LUMIGAN®) Challenge; Sponsored by Vistakon
- 11/09 to 6/10: RPS ADENO DETECTOR IV™ STUDY PROTOCOL; To compare the sensitivity and specificity of the RPS Adeno Detector IV™ at detecting the presence of adenovirus to Cell Culture; Sponsored by Rapid Pathogen Screening (RPS)
- 11/09 to 02/10: RPS HSV DETECTOR STUDY PROTOCOL; To compare the sensitivity and specificity of the RPS HSV Detector at detecting the presence of HSV related keratitis to both cell culture and PCR. Sponsored by Rapid Pathogen Screening (RPS)
- 10/09 to 02/10: Tecnis Multifocal IOL vs Restor Pilot Study: Sponsored by Abbott Medical Optics
- 10/09 to present Corneal Collagen crosslinking with riboflavin for Keratoconus, Pellucid, RK, and Post-LASIK ectasia; Sponsored by CXLUSA; Clinicaltrials.gov identifier: NCT01024322
- 10/09 to 07/10 Measurement of accommodation with the COAS High Definition Wavefront Aberrometer; Sponsored by Abbott Medical Optics
- 06/09 to 07/10 The PHACO Study (Prospective Health Assessment of Cataract Patients' Ocular Surface); Multicenter Study, funded by Allergan
- 06/09 to 10/09 Determine the Presence of Blepharitis in Patients undergoing Cataract Surgery; Multicenter study, funded by Inspire.
- 03/09 to 08/09 A Randomized, Multi-Center, Double-Blind, Placebo-Controlled, Parallel-Group Safety and Efficacy Study of Azithromycin Ophthalmic Solution, 1% versus Placebo for Four Weeks in Subjects with Blepharitis (protocol # 044-102): study sponsored by Inspire Pharmaceuticals
- 02/09 to 10/09: A three-month, investigator-masked, randomized, multicenter, parallel, clinical trial comparing the efficacy of Combigan® (fixed combination of 0.2% brimonidine tartrate and 0.5% timolol maleate ophthalmic solution) versus Xalatan® (latanoprost 0.005% ophthalmic solution) in subjects with ocular hypertension or open-angle glaucoma. (Study #: GMA-COM-08-008); sponsored by Allergan
- 2/09 to 7/09 A Multi-Center, Parallel-Group, Double-Masked, Randomized, Placebo-Controlled Study of the Effects of diquafosol tetrasodium Ophthalmic Solution, 2% in Subjects with Dry Eye Disease and a Central Corneal Staining Score of 3 (NEI Scale). (protocol # 03-113): study sponsored by Inspire Pharmaceuticals
- 2/09 to 5/09 An Open-Label Study To Assess The Efficacy Of A Combination Povidone-Iodine 0,4% (w/w)/Dexamethasone 0.1% (w/w) Ophthalmic Suspension In The Treatment Of Acute Adenoviral Conjunctivitis; (OOG-AVC-001); sponsored by Foresight Biotherapeutics
- 2/09 to 6/09 PPL GLAU 06: A Partially Masked, Phase 2 Study of the Latanoprost Punctal Plug Delivery System (L-PPDS) in Subjects With Ocular Hypertension or Open-Angle Glaucoma (sponsored by QLTI)
- 1/09 to 10/09: PPL GLAU 03: An Open-Label, Phase 2 Study of the Latanoprost Punctal Plug Delivery System (L-PPDS) in Subjects With Ocular Hypertension or Open Angle Glaucoma (sponsored by QLTI)
- 12/08 to 1/09: A Multicenter, Randomized, Double-Masked, Vehicle-Controlled Pilot Study of the Efficacy and Safety of Cyclosporine A Ophthalmic Solution (ST-603), 0.1% and 0.2% Compared to Vehicle in Subjects With Dry Eye Disease; (Protocol # ST-603-010); Sponsored by Sirion
- 11/08 to 7/2010 Evaluation of outcomes using the AMO advanced Customvue™ iLasik procedure (Wavescan Wavefront® System, Star S4 IR™ Excimer Laser System and Intralase™ FS System); Sponsored by AMO-Abbott
- 11/08 to present A Device Evaluation Study to Assess the Physical and Clinical Performance of Prototype Punctal Plug Design Iterations (PP Dev 01); Sponsored by QLTI

## William B. Trattler, MD

- 09/08 to 11/08: Evaluation of the Crystalens HD (Multicenter (5 sites) outcomes (study sponsored by B&L)
- 7/08 to 1/09: Evaluation Of The Rezoom™ Multifocal And Crystalens™ Accommodating Intraocular Lenses (AMO )
- 7/08 to 1/09: Evaluation Of The Rezoom™ Multifocal And Restor Multifocal Intraocular Lenses (AMO)
- 7/08 to 11/08: Efficacy and Safety of Xibrom™ (Bromfenac Ophthalmic Solution) 0.09% QD vs. Placebo QD for Treatment of Ocular Inflammation and Pain Associated with Cataract Surgery; Clinical Trial Protocol: CL-S&E-0415081-P (Ista)
- 6/08 to 11/08: Evaluation Of Artificial Tears (Blink Tears) In Post-Lasik Patients (AMO)
- 4/08 to 8/09: Protocol UVX-002: Safety and Effectiveness of the UV-X System for Corneal Collagen Cross-Linking in Eyes with Progressive Keratoconus
- 4/08 to 8/09: Protocol UVX-003: Safety and Effectiveness of the UV-X System for Corneal Collagen Cross-Linking in Eyes with Corneal Ectasia after Refractive Surgery
- 4/08 to 12/08: Wavetec: a multi-center, prospective study of the wavetec vision systems aberrometer performed in subjects undergoing cataract surgery
- 03/08 to 6/08: A Multi-Center, Open-Label, Randomized Pilot Study of the Safety and Efficacy of AzaSite® Ophthalmic Solution, 1% in Combination with Mechanical Therapy versus Mechanical Therapy Alone in Subjects with Blepharitis (sponsored by Inspire pharmaceuticals); Protocol Number: 041-105
- 12/07 to 11/08: A Multi-Center, Double-Masked, Randomized, Controlled, Parallel-Group, Three-Month Study (Plus Three-Month, Masked Extension) to Evaluate the Safety and Efficacy of Twice-Daily Administered Cyclosporine Ophthalmic Emulsion 0.05% (RESTASIS®) in Accelerating the Recovery of Corneal Sensitivity in Post-LASIK Patients; PROTOCOL NUMBER: 192371-014-00 (Allergan)
- 12/07 to 12/07: SURFACE: Surveillance of Resistance to Formulations of Antimicrobials in Cultures of the Eye (Allergan)
- 11/07 to 1/08: A Multi Center, Double Masked, Randomized Parallel Group Study Evaluating the Safety and Efficacy of a New Formulation of Ketorolac Tromethamine 0.45% Ophthalmic Solution Compared with Vehicle Administered Preoperatively and Twice-Daily Postoperatively for Two Weeks for the Treatment of Anterior Segment Inflammation, Pain, and Inhibition of Surgically Induced Miosis Following Cataract Extraction with Posterior Chamber Intraocular Lens (IOL) Implantation; Protocol #:191578-006 (Allergan); enrollment complete
- 11/07 to 1/08: Efficacy and Safety of Bromfenac Ophthalmic Solution 0.18% QD vs. Xibrom™ (Bromfenac Ophthalmic Solution) 0.09% QD for Treatment of Ocular Inflammation, Pain, and Photophobia Associated with Cataract Surgery; Enrollment Complete
- 10/07 to 4/08: A Multi-Center, Double-Masked, Randomized, Two-Arm, Parallel-Group Study to Compare the Efficacy, Safety and Acceptability of Optive™ Unit-Dose Eye Drops with Refresh Plus® Unit-Dose Lubricant Eye Drops for Three Months in Subjects following LASIK Refractive Surgery Status: PROTOCOL NUMBER: AG9818-001-00 (Allergan)
- 8/07 to 5/08: A 6 Day, Phase 3, Multicenter, Randomized, Double-Masked, Parallel Study to Compare the Safety and Efficacy of Gatifloxacin 0.5% Ophthalmic Solution BID with that of Vehicle in the Treatment of Acute Bacterial Conjunctivitis; PROTOCOL #: 198782-004-00 (Allergan)
- 8/07 to 4/08: A Phase 3 Double-Masked, Randomized Study of the Safety and Effectiveness of DYME (Brilliant Blue) as an Agent for Selective Staining of the Anterior Capsule during Cataract Surgery; Protocol AQNA-DY001: (Aqumen Biopharmaceuticals N.A., Inc.)
- 8/07 to 4/08: “A Multicenter, Masked Evaluation of Ocular Surface Tolerability Associated with Bimatoprost 0.03%, Travoprost 0.004% (BAK free) or Latanoprost 0.005% Therapy in pts with Glaucoma or OHTN”
- 7/07 to 9/08: Phase 3 study: An Open-Label, Safety Evaluation of Cyclosporine A Ophthalmic Solution, 0.1% (ST-603) Administered Twice Daily for 12 Months to Subjects With Dry Eye Syndrome (ST-603-006)
- 6/07 to 11/07: Phase 3 Study of the Efficacy and Safety of Cyclosporine Ophthalmic Solution, 0.1% (ST-603) Compared to Vehicle in Subjects With Moderate to Severe Dry Eye Syndrome( ST-603-005)

# William B. Trattler, MD

- 6/07 to 4/08: XPF2 Study: Bromfenac BID Plus Prednisolone Acetate BID versus Bromfenac BID Plus Prednisolone QID for the Prevention of Cystoid Macular Edema and Retinal Thickening (Principle Investigator Carlos; Educational Grant provided by Ista Pharmaceuticals)
- 3/07 to 11/07: Lenstec™ Softec HDTM Posterior Chamber IOL Clinical Study (Phase 3 study); enrollment complete
- 3/07 to 8/07: Phase 3 Multicenter, Randomized, Double-Masked, Placebo-Controlled Study of Difluprednate in the Treatment of Inflammation Following Ocular Surgery (Sirion Therapeutics study # ST-601A-002a)
- 11/06 to 1/08: I-Stent Trabecular Bypass Micro Stent in Combination with Cataract Surgery in Subjects with Open-Angle Glaucoma, GC-003, Glaukos Corporation (Phase 3 study): Enrollment Complete
- 10/06 to 1/08: Efficacy of Topical Cyclosporine Ophthalmic Emulsion for the Prevention and Treatment of Dry Eye Symptoms Following LASIK or Photorefractive Keratectomy: Enrollment Complete
- 10/06 to 3/07: VISTAKON® (senofilcon A) Contact Lens Material, A Retrospective Bandage Lens Usage; Review of the Acuvue Oasys as a Bandage Contact Lens. (Vistakon study CR-1550)
- 11/06 to 10/07: Lenstec™ TetraFlex™ Accommodating Posterior Chamber IOL Clinical Investigation (IDE G050048); enrollment complete
- 1/06 to 04/07: Evaluation of the IOP-Lowering Effect & Tolerability of Bimatoprost 0.03% (Lumigan®) Compared with Travoprost 0.004% (Travatan®) in Patients with Glaucoma or OHTN (Allergan MA-LUM01 study)
- 9/06 to 12/06: A Randomized Evaluation of Two Surgical Kits: Gatifloxacin, Ketorolac LS, and Pred Forte Compared with Moxifloxacin, Nepafenac, and EconoPred in Patients Undergoing Cataract Surgery. Complete
- 8/06 to 9/08: A Multicenter Study on a Rapid screening tests for detection of HSV in tears; Rapid Pathogens Screening, Inc
- 7/06-12/06: A Randomized, Double-Masked Safety and Efficacy Study of FID #109980 Compared to FID #110656 in the Treatment of Dry Eye; Phase 3 Dry eye study sponsored by Alcon.
- 7/06-11/06 Comparison of Topical Xibrom™ vs Acular LS for the Control of Pain, Photophobia, and Discomfort Following PRK; Investigator initiated study, funded by Ista pharmaceuticals
- 6/06-11/06 Efficacy and Safety of Topical Bromfenac Ophthalmic Solution 0.18% vs. Placebo for Treatment of Ocular Inflammation & Pain and following Cataract Surgery ISTA-BR-CS02 Protocol; Phase 3 study; Ista pharmaceuticals; Study completed
- 6/06-11/06 A multi-center, randomized, double-masked, parallel clinical trial to evaluate the clinical and microbial efficacy of 0.6% ISV-403 compared to Vigamox™ in the treatment of bacterial conjunctivitis. Phase 3 study; Bausch & Lomb
- 5/06-4/07 A Multicenter Evaluation of Methods to Reduce Hyperemia Associated with Bimatoprost Therapy for Glaucoma or Ocular Hypertension; (Educational Grant provided by Allergan)
- 5/06-12/06 Comparison of Bimatoprost 0.03% Monotherapy vs. Dual Therapy with Travoprost 0.004% and Timolol 0.5% in Patients with Glaucoma. (Educational Grant provided by Allergan)
- 5/06-4/07 Brimonidine Purite 0.15% versus Dorzolamide 2% Used as Adjunctive Therapy to Latanoprost (Educational Grant provided by Allergan)
- 2/06-7/06 Comparison of Pred Forte to Acular & Pred Forte for post cataract surgery inflammation (Allergan);
- 1/06-4/06 Double-masked study of Acular LS vs Nevanac for pain control following PRK (Educational Grant provided by Allergan);
- 11/05-3/06 Double-masked study of Acular LS vs Nevanac for pain control following flapless epi-LASIK (Educational Grant provided by Allergan);
- 10/5 -3/06 Double-masked comparison of Restasis vs Refresh for Patients with Contact Lens Intolerance (Educational Grant provided by Allergan);
- 5/05-6/05 Comparison of Soothe vs Genteal in Patients with Dry Eye due to Computer Vision Syndrome; (Educational Grant provided by Alimera Sciences)

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.